[go: up one dir, main page]

WO2025056677A1 - Dasiglucagon destiné à être utilisé dans le traitement de l'hyperinsulinisme congénital - Google Patents

Dasiglucagon destiné à être utilisé dans le traitement de l'hyperinsulinisme congénital Download PDF

Info

Publication number
WO2025056677A1
WO2025056677A1 PCT/EP2024/075495 EP2024075495W WO2025056677A1 WO 2025056677 A1 WO2025056677 A1 WO 2025056677A1 EP 2024075495 W EP2024075495 W EP 2024075495W WO 2025056677 A1 WO2025056677 A1 WO 2025056677A1
Authority
WO
WIPO (PCT)
Prior art keywords
dasiglucagon
treatment
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/075495
Other languages
English (en)
Inventor
Jelena IVKOVIC
Minna BRÆNDHOLT OLSEN
Klara OWEN
Eva BØGE
Sune BIRCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of WO2025056677A1 publication Critical patent/WO2025056677A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to glucagon analogues, in particular to dasiglucagon and its medical use.
  • Dasiglucagon has utility in the treatment of hypoglycaemia, e.g., in the treatment of congenital hyperinsulinism (CHI).
  • CHI congenital hyperinsulinism
  • CHI Congenital hyperinsulinism
  • pancreatic p-cells secrete insulin irrespective of blood glucose concentration (Banerjee et al. Yau et al.), which causes persistent and often severe hypoglycaemia in neonates and early childhood and results in compromised neurological outcome (brain damage, seizures and neurodevelopmental impairment) in up to 50% of infants and children.
  • CHI can be acquired or genetic, with both forms associated with an adverse impact on neurodevelopment in up to 50% of patients (Arnoux et al.; Radcliffe et al.).
  • Other forms of neonatal hyperinsulinism tend to be transient in nature and are often associated with perinatal stress or maternal gestational diabetes (Banerjee et al.).
  • the genetic forms can be single gene defects with symptoms related predominately to hypoglycaemia secondary to hyperinsulinism, or may occur as part of a syndrome where hypoglycaemia secondary to hyperinsulinism is only one manifestation of the syndrome.
  • a number of genes have been identified that cause hyperinsulinism, with many involved in the insulin secretory pathway (De Cosio et al.).
  • the genetic forms of CHI are generally classified as either focal, diffuse, or atypical according to histology (Banerjee et al.).
  • CHI Current treatments for CHI include pharmacotherapy, nutritional support, and surgical management.
  • hyperinsulinism There is only one drug approved for the treatment of hyperinsulinism, approved in 1977.
  • This drug, diazoxide, a potassium channel activator has significant side effects and complications, is only effective in less than 50% of patients with genetic forms of hyperinsulinism and is ineffective in those with inactivating mutations in the ATP-sensitive K + channel genes (who represent the largest proportion of patients with known genetic cause (De Cosio et al.)).
  • Several unapproved drugs have been utilised for the treatment of CHI as well including calcium channel blockers, and short and long-acting somatostatin analogues, with observational studies reporting variable success.
  • pancreatic enzyme replacements In a proportion of patients with diffuse or atypical CHI, medical and nutritional management is inadequate to ensure satisfactory glycaemic stability. In such cases, subtotal or near-total pancreatectomy needs to be undertaken to reduce the frequency of hypoglycaemia. However, such procedures are complicated by the risk of persistent hypoglycaemia in 40-60% patients (Arya et al. Meissner et al.), the need for pancreatic enzyme replacements, and inevitable progression to insulinrequiring diabetes.
  • Human preproglucagon is a 158 amino acid precursor polypeptide that is differentially processed in the tissues to form a number of structurally related proglucagon-derived peptides, including glucagon (Glu or GCG), glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and oxyntomodulin (OXM). These molecules are involved in a wide variety of physiological functions, including glucose homeostasis, insulin secretion, gastric emptying and intestinal growth, as well as regulation of food intake.
  • Glu or GCG glucagon
  • GLP-1 glucagon-like peptide-1
  • GLP-2 glucagon-like peptide-2
  • OXM oxyntomodulin
  • Native glucagon is a 29-amino acid peptide that corresponds to amino acids 53 to 81 of preproglucagon.
  • Glucagon helps maintain the level of glucose in the blood by binding to glucagon receptors on hepatocytes, causing the liver to release glucose - stored in the form of glycogen - through glycogenolysis. As these stores become depleted, glucagon also stimulates the liver to synthesize additional glucose by gluconeogenesis. This glucose is released into the bloodstream, preventing the development of hypoglycaemia.
  • glucagon is not approved for use in CHI but has been shown to be effective in the treatment of this disease, in particular for short-term treatment.
  • Glucagon is commonly used after diagnosis to stabilise patients before initiation of other medical or surgical treatments and may be administered as an intravenous infusion or as a repeated subcutaneous injection. Furthermore, glucagon is administered as single subcutaneous doses to treat severe hypoglycaemic episodes.
  • CHI Syneromon-Estebanez et al., Cederblad et al.
  • IV intravenous
  • SC bolus subcutaneous
  • intramuscular injections often used during or after diagnosis to stabilise CHI patients before initiation of other medical or surgical treatments.
  • native glucagon has relatively low physical and chemical stability per se. Hence, it cannot be used for long-term treatment. Long-term glucagon treatment is thus complicated by the fact that currently available glucagon products are unstable in nature and form fibrils within hours after reconstitution. This fibril formation may lead to infusion set clotting, catheter obstruction and dosing errors that may cause acute severe hypoglycaemia. In a home-care setting, this fibril formation and associated risk of dosing errors carry the risk of hypoglycaemic events, which is a major barrier for using currently marketed glucagon products for long-term treatment of patients with CHI. Hence, while glucagon is used for CHI in a hospital setting, as described above, there are currently no approved glucagon products for long-term (home) use.
  • a glucagon analogue, dasiglucagon, or a pharmaceutically acceptable salt or solvate thereof can be efficiently and safely used in subjects with CHI, in particular for long-term treatments.
  • Dasiglucagon is a glucagon analogue under development for the prevention and treatment of hypoglycaemia in patients with CHI.
  • WO 2014/016300 describes glucagon analogues, in particular dasiglucagon (compound number 21 or SEQ ID NO.: 22 in WO 2014/016300).
  • Dasiglucagon is currently approved as a rescue treatment for severe hypoglycaemia in pediatric and adult patients with diabetes (Zealand Pharma, Dasiglucagon (Zegalogue) US Prescribing Information).
  • dasiglucagon Like human glucagon, dasiglucagon comprises 29 amino acids, with seven amino acid substitutions introduced to improve stability in aqueous media, enabling dasiglucagon to be formulated as a ready-to-use aqueous solution deliverable via SC injection or SC infusion (Hovelmann et al.).
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof is particularly effective in certain patient subgroups and in combination or absence of certain standard of care therapies. Additionally, it was found that dasiglucagon was more effective in the treatment of hypoglycaemia than could have been anticipated by previous publications. Finally, the inventors found that dasiglucagon was surprisingly effective in the treatment of nocturnal hypoglycaemia.
  • the present invention provides dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating CHI.
  • the method of treating CHI does not comprise the administration of diazoxide.
  • the method of treating CHI additionally comprises coadministration of at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus to a patient suffering from CHI (a CHI patient).
  • the CHI patient has a body weight of 5 to ⁇ 10 kg at the start of the treatment, and in preferred embodiments, the CHI patient has not had a pancreatectomy before the start of the treatment.
  • the present invention provides dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating CHI, wherein the treatment reduces the time in hypoglycaemia, wherein the time in hypoglycaemia is defined as a glucose level of ⁇ 70 mg/dL measured by continued glucose monitoring (CGM).
  • the treatment reduces the rate of hypoglycaemic episodes.
  • the rate of hypoglycaemic episodes is defined as the number of CGM-detected episodes per week.
  • a single CGM-detected hypoglycaemic episode is defined as a glucose level of ⁇ 70 mg/dL measured by continued glucose monitoring (CGM) for 15 minutes and up until 60 minutes from the start of the episode even if normoglycemia (>70 mg/dL) was not reached within this time.
  • CGM glucose monitoring
  • a new episode of hypoglycaemia begins when the next CGM values below 70 mg/dL was measured for at least 15 minutes.
  • the present invention further provides dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating nocturnal hypoglycaemia in CHI patients.
  • the invention provides dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of preventing nocturnal hypoglycaemia in CHI patients.
  • the treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof may be for 4 or 8 weeks.
  • treatment with the standard of care is concomitant.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof is administered at a dose of at least 10 pg/h.
  • the dose may be increased by 10 pg/h every two hours from the start of treatment to a maximum rate of 70 pg/h.
  • the method of treatment is used in paediatric patients, optionally wherein the patients are between 3 months and 12 years of age (both inclusive).
  • Figure 1 Visualisation of the sequence of dasiglucagon (SEQ ID NO.: 1).
  • FIG. 1 IV glucose infusion rate (GIR) during Part 1 of Example 1.
  • Figure 4 Total carbohydrates (g) during part 1 of Example 1.
  • Figure 5 Trial scheme as described in Example 2.
  • Figure 6 CGM percent time in hypolgycaemia ⁇ 70 mg/dL (%) by treatment group of Example 2.
  • Figure 7 CGM-detected hypoglycaemic episode rate (per week) by treatment group of Example 2.
  • Figure 8 CGM-detected clinically significant hypoglycaemic episode rate (per week) by treatment group of Example 2.
  • Figure 9 Subgroup analysis of efficacy of dasiglucagon for Example 1 showing weighted mean IV glucose infusion rate (GIR) (mg/kg/min) by genetic type - part 1 FAS population.
  • GIR weighted mean IV glucose infusion rate
  • Figure 10 Subgroup analysis of efficacy of dasiglucagon for Example 2.
  • Figure 11 Subgroup analysis of efficacy of dasiglucagon for Example 2 by age groups - week 2-4 FAS population; continuous glucose monitoring (CGM) percent time ⁇ 70 mg/dL (3.9 mmol/L).
  • CGM continuous glucose monitoring
  • Figure 12 Subgroup analysis of efficacy of dasiglucagon for Example 2 by baseline body weight groups- week 2-4 FAS population; continuous glucose monitoring (CGM) percent time ⁇ 70 mg/dL (3.9 mmol/L).
  • CGM continuous glucose monitoring
  • Figure 13 Subgroup analysis of efficacy of dasiglucagon for Example 2 by baseline diazoxide use - week 2-4 FAS population; continuous glucose monitoring (CGM) percent time ⁇ 70 mg/dL (3.9 mmol/L).
  • CGM continuous glucose monitoring
  • Figure 14 Subgroup analysis of efficacy of dasiglucagon for Example 2 by baseline use of a somatostatin analogue - week 2-4 FAS population; continuous glucose monitoring (CGM) percent time ⁇ 70 mg/dL (3.9 mmol/L).
  • CGM continuous glucose monitoring
  • Figure 15 Subgroup analysis of efficacy of dasiglucagon for Example 2 by pancreatectomy at baseline- week 2-4 FAS population; continuous glucose monitoring (CGM) percent time ⁇ 70 mg/dL (3.9 mmol/L).
  • CGM continuous glucose monitoring
  • SEQ ID NO. 1 amino acid sequence of Dasiglucagon - HSQGTFTSDYSKYLD-Aib- ARAEEFVKWLEST - which corresponds to SEQ ID NO: 22 in WO 2014/016300, Hy- HSQGTFTSDYSKYLD-Aib-ARAEEFVKWLEST-OH.
  • a "Hy-" moiety at the /V-terminus of the sequence in question indicates a hydrogen atom, while an "-OH” moiety at the C-terminus of the sequence indicates a hydroxy group.
  • “Aib” stands for 2-methylalanine, also known as alpha-aminoisobutyricacid.
  • hypoglycaemia also referred to as low blood sugar or low blood glucose
  • hypoglycaemia is a fall in blood sugar to levels below normal, typically below 70 mg/dL (3.9 mmol/L).
  • Blood sugar levels are generally maintained between 70 and 110 mg/dL (3.9-6.1 mmol/L).
  • 70 mg/dL (3.9 mmol/L) is the lower limit of normal glucose, symptoms of hypoglycaemia usually do not occur until 54 mg/dL (3.0 mmol/L) or lower.
  • hypoglycaemia is defined as a blood glucose level of below 70 mg/dL (3.9 mmol/L).
  • Clinically significant hypoglycaemia is defined as a blood glucose level of 54 mg/dL (3.0 mmol/L) or lower.
  • hypoglycaemia In the context of the present invention, a variety of approaches to determine the extent of hypoglycaemia may be used.
  • the "percent time in hypoglycaemia” is defined as the percent time with a glucose level of ⁇ 70 mg/dL, for example measured with the Continuous Glucose Monitoring method, see below for further details.
  • the "percent time in clinically significant hypoglycaemia” is defined as the percent time with a glucose level of ⁇ 54 mg/dL, for example measured with the Continuous Glucose Monitoring method, see below forfurther details.
  • the "rate of hypoglycaemic episodes" is defined as the number of episodes per week, wherein a single hypoglycaemic episode is defined as a glucose level of ⁇ 70 mg/dL for at least 15 minutes and up until 60 minutes from the start of the episode even if normoglycaemia (>70 mg/dL) was not reached within this time, wherein a new episode of hypoglycaemia begins when the next values below 70 mg/dL are measured for at least 15 minutes.
  • the "rate of clinically significant hypoglycaemic episodes" is defined as the number of episodes per week, wherein a single clinically significant hypoglycaemic episode is defined as a glucose level of ⁇ 54 mg/dL for at least 15 minutes and up until 60 minutes from the start of the episode even if normoglycaemia (>70 mg/dL) was not reached within this time, wherein a new episode of clinically significant hypoglycaemia begins when the next values below 54 mg/dL are measured for at least 15 minutes.
  • SMPG refers to "Self-Monitored Plasma Glucose".
  • the subject's glucose levels are measured at least three times daily, preferably before main meals, and also in case of suspected hypoglycaemia. Readings are typically collected in the subject's diary.
  • SMPG can be carried out with any suitable glucose meter, for example, the StatStrip Xpress2 manufactured by Nova Biomedical, Waltham, MA, USA.
  • CGM refers to "Continuous Glucose Monitoring". The method is primarily distinguished over SMPG in that it offers a continuous readout of the subject's glucose level instead of discrete values.
  • CGM can be carried out by a variety of suitable glucose meters or continuous glucose monitors, for example, the Dexcom G4 or G6 by Dexcom Inc., San Diego, CA, USA.
  • glucose levels are measured with the CGM method.
  • mean also known as the arithmetic mean or arithmetic average, is a measure of central tendency of a finite set of numbers: specifically, the sum of the values divided by the number of values.
  • the term “median” expresses the value separating the higher half from the lower half of a data sample, a population, or a probability distribution. For a data set, it may be thought of as "the middle" value.
  • hypoglycaemia is defined as hypoglycaemia occurring between 10 pm (excluded) and 6 am (excluded).
  • a typical measure for nocturnal hypoglycaemia in the context of the present invention is the mean number of nocturnal hypoglycaemic events (episodes)/week as described above.
  • nocturnal hypoglycaemia In the specific context of nocturnal hypoglycaemia, a typical measure is the mean number of nocturnal hypoglycaemic events (episodes)/week with onset between 10 pm (excluded) and 6 am (excluded)).
  • a "single CGM-detected hypoglycaemic episode” is defined as CGM ⁇ 3.9 mmol/L; 70 mg/dL (or ⁇ 3.0 mmol/L; 54 mg/dL) for 15 minutes and up until 60 minutes from the start of the episode even if normoglycaemia (>3.9 mmol/L) is not reached within this time.
  • a "new episode of nocturnal hypoglycaemia” is defined as when the next CGM value was below 3.9 mmol/L; 70 mg/dL (or ⁇ 3.0 mmol/L; 54 mg/dL) for at least 15 min.
  • native glucagon refers to native human glucagon.
  • Native glucagon is a 29-amino acid peptide that corresponds to amino acids 53 to 81 of preproglucagon.
  • Glucagon helps maintain the level of glucose in the blood by binding to glucagon receptors on hepatocytes, causing the liver to release glucose - stored in the form of glycogen -through glycogenolysis. As these stores become depleted, glucagon also stimulates the liver to synthesize additional glucose by gluconeogenesis. This glucose is released into the bloodstream, preventing the development of hypoglycaemia. See, e.g., SEQ ID NO.: 1 in WO 2014/016300.
  • Dasiglucagon is a glucagon analogue, as described above. In particular, it is a modified human glucagon. Dasiglucagon comprises 29 amino acids and is distinct from glucagon through its amino acid sequence. This improves, inter alia, water solubility of dasiglucagon compared to glucagon, as shown in WO 2014/016300. Dasiglucagon consists of 29 amino acids, similar to endogenous glucagon:
  • WO 2014/016300 describes glucagon analogues, including dasiglucagon (compound 21 or SEQ ID NO.: 22 in WO 2014/016300).
  • Dasiglucagon has the molecular formula C152H222N38O50.
  • a visualisation illustrating the structure of Dasiglucagon is shown in Figure 1.
  • Dasiglucagon demonstrates in vitro agonist activity at the human glucagon receptor, with EC50 values of 0.0095 nM and 0.030 nM, respectively as reported in WO 2014/016300.
  • Dasiglucagon may also be provided in the form of a salt or other derivative (dasiglucagon or a pharmaceutically acceptable salt or solvate thereof). Salts include pharmaceutically acceptable salts, as defined herein.
  • Dasiglucagon may be manufactured by standard chemical synthetic methods, or by using recombinant expression systems, or by any other suitable state-of-the-art method.
  • a nonlimiting example for the synthesis of dasiglucagon is provided in the examples section.
  • dasiglucagon may be synthesized in a number of ways, including, inter alia, methods comprising:
  • dasiglucagon it may be preferable to synthesize dasiglucagon by means of solid-phase or liquid-phase peptide synthesis, the methodology of which is well known to persons of ordinary skill in the art of peptide synthesis. Reference may also be made in this respect to, for example, WO 98/11125 and Fields, G.B. et al., 2002, "Principles and practice of solid-phase peptide synthesis", in: Synthetic Peptides (2nd Edition), and examples provided therein. Starting on p. 39 of WO 2014/016300, general synthesis procedures for glucagon analogues are provided.
  • an expression vector may comprise the following features in the 5'-3' direction and operably linked: a promoter for driving expression of the nucleic acid fragment, optionally a nucleic acid sequence encoding a leader peptide enabling secretion (to the extracellular phase or, where applicable, into the periplasma), the nucleic acid fragment encoding the peptide of the invention, and optionally a nucleic acid sequence encoding a terminator.
  • the expression vector also may comprise additional features such as selectable markers and origins of replication. When operating with expression vectors in producer strains or cell lines, it may be preferred that the vector is capable of integrating into the host cell genome. The skilled person will be familiar with suitable vectors, and will be able to design one according to the specific requirements in question.
  • Vectors may be used to transform host cells to produce dasiglucagon.
  • Such transformed cells can be cultured cells or cell lines used for propagation of the nucleic acid fragments and vectors, or may be used for recombinant production of dasiglucagon.
  • the transformed cells are micro-organisms such as bacteria (e.g., species of Escherichia (e.g., E. coli), Bacillus (e.g., B. subtilis), Salmonella or Mycobacterium (preferably non-pathogenic, e.g., M. bovis BCG)), yeasts (e.g., Saccharomyces cerevisiae or Pichia pastoris), or protozoans.
  • bacteria e.g., species of Escherichia (e.g., E. coli), Bacillus (e.g., B. subtilis), Salmonella or Mycobacterium (preferably non-pathogenic, e.g., M. bovis BCG)
  • yeasts e.g., Saccharomyces cerevisiae or Pichia pastoris
  • protozoans e.g., the transformed cells may be derived from a multicellular organism, e.g., the cells may be fungal cells, insect cells, algal cells, plant cells,
  • the transformed cell may be capable of replicating the nucleic acid construct.
  • Cells expressing the nucleic acid constructs are useful and may be used for small-scale or large-scale preparation of dasiglucagon.
  • Dasiglucagon as defined above may be used as a pharmaceutically acceptable salt or solvate in the context of the present invention.
  • salts in general acid addition salts or basic salts.
  • Acid addition salts include salts of inorganic acids and salts of organic acids.
  • suitable acid addition salts include hydrochloride salts, phosphate salts, formate salts, acetate salts, trifluoroacetate salts and citrate salts.
  • suitable acid addition salts include hydrochloride salts, phosphate salts, formate salts, acetate salts, trifluoroacetate salts and citrate salts.
  • basic salts include salts where the cation is selected from alkali metal ions, such as sodium and potassium, alkaline earth metal ions, such as calcium, as well as substituted ammonium ions, e.g.
  • R and R' independently designate optionally substituted Ci-ealkyl, optionally substituted C2-ealkenyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • R and R' independently designate optionally substituted Ci-ealkyl, optionally substituted C2-ealkenyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • Other examples of pharmaceutically acceptable salts are described in Remington's Pharmaceutical Sciences, 17th edition. Ed. Alfonso R. Gennaro (Ed.), Mack Publishing Company, Easton, PA, U.S.A., 1985 and more recent editions, and in the Encyclopaedia of Pharmaceutical Technology.
  • solvate in the context of the present invention refers to a complex of defined stoichiometry formed by a solute (in casu a compound, or a pharmaceutically acceptable salt thereof, of the present invention) and a solvent.
  • Relevant solvents include, but are not limited to, water, ethanol and acetic acid.
  • Solvates in which the solvent molecule in question is water are generally referred to as "hydrates”.
  • dasiglucagon (or a pharmaceutically acceptable salt or solvate thereof as described above) may be comprised in a pharmaceutical composition (also referred to as pharmaceutical formulation) further comprising a pharmaceutically acceptable salt and/or excipient as defined herein.
  • compositions may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • excipient refers to a vehicle, diluent or adjuvant that is administered with the active ingredient.
  • Such pharmaceutical excipients can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and similar. Water or saline aqueous solutions and aqueous dextrose and glycerol solutions, particularly for injectable solutions, are particularly used as vehicles.
  • Suitable pharmaceutical vehicles are described in Remington's Pharmaceutical Sciences by E.W. Martin, 21st Edition, 2005; or Handbook of Pharmaceutical Excipients, Rowe C. R.; Paul J. S.; Marian E. Q., sixth Edition.
  • Suitable pharmaceutically acceptable vehicles include, e.g., water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, monoglycerides and diglycerides of fatty acids, fatty acid esters petroetrals, hydroxymethyl cellulose, polyvinylpyrrolidone and similars.
  • Aqueous solutions are particularly preferred. Therefore, particularly useful embodiments of liquid pharmaceutical compositions are aqueous compositions, i.e., compositions comprising water. Such compositions may be in the form of an aqueous solution or an aqueous suspension. Preferred embodiments of aqueous pharmaceutical compositions are aqueous solutions.
  • aqueous composition or “aqueous formulation” will normally refer to a composition comprising at least 50% by weight (50% w/w) of water, preferably at least 75% w/w of water, more preferably at least 80% w/w of water, more preferably at least 85% w/w of water, more preferably at least 90% w/w of water, most preferably at least 95% w/w of water.
  • aqueous solution will normally refer to a solution comprising at least 50 % w/w of water
  • aqueous suspension to a suspension comprising at least 50 % w/w of water.
  • glucagon analogues such as dasiglucagon described therein can avoid including a polar aprotic solvent in the liquid formulation, such as the use of dimethyl sulfoxide (DMSO) as used in WO 2017/053822 and WO 2014/124151 with the disadvantages that this brings to the formulations in use.
  • aqueous compositions of the present invention substantially do not include aprotic polar solvents, such as dimethyl sulfoxide (DMSO).
  • the aqueous formulations include less than 5% by volume (v/v) aprotic solvent, more preferably less than 2% by volume (v/v) aprotic solvent and even more preferably less than 1% by volume (v/v) aprotic solvent.
  • Water is the sole solvent used to make the aqueous liquid formulations according to certain embodiments.
  • composition or formulation comprising dasiglucagon is preferably a stable composition or formulation.
  • a “stable" composition or formulation is one in which the peptide therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage. Preferably, the composition or formulation essentially retains its physical and chemical stability, as well as its biological activity upon storage. The storage period is generally selected based on the intended shelf-life of the formulation.
  • the compositions or formulations of the present invention are provided as stable liquid formulations, e.g. stable aqueous liquid formulations.
  • Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev.
  • stable formulations include formulations in which at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, and most preferably at least 99% of the glucagon analogue does not degrade in the formulation after it has been stored at 2-8°C for 18 months. It is also possible to test stability under accelerated condition which generally use an increased storage temperature in order to assess stability over reduced time periods. For example, storage at 25 ⁇ C, sometimes referred to as under accelerated conditions, may be used to assess stability over a period of 13, 26, 39 or 52 weeks. By way of comparison, the use of other buffers such as phosphate buffer or histidine buffer leads to stability levels that are generally less than 80% after storage for a corresponding period.
  • Stability can be measured at a selected temperature for a selected time period, for example using elevated temperature to reduce the period over which a formulation is tested.
  • storage at a temperature between 2 to 8°C denotes storage under normal refrigerated conditions.
  • the composition or formulation is stable under such conditions for at least 6 months, more preferably at least 12 months, more preferably at least 18 months, more preferably at least 24 months.
  • Stability can be evaluated qualitatively and/or quantitatively in a variety of different ways, including evaluation of aggregate formation (e.g., using size exclusion chromatography, UV light scattering, dynamic light scattering, circular dichroism, by measuring turbidity, and/or by visual inspection); by assessing charge heterogeneity using cation exchange chromatography, image capillary isoelectric focusing (icIEF) or capillary zone electrophoresis; amino-terminal or carboxyterminal sequence analysis; mass spectrometric analysis; SDS-PAGE analysis to compare reduced and intact antibody; peptide map (for example tryptic or LYS-C) analysis; evaluating biological activity or antigen binding function of the antibody; etc.
  • aggregate formation e.g., using size exclusion chromatography, UV light scattering, dynamic light scattering, circular dichroism, by measuring turbidity, and/or by visual inspection
  • charge heterogeneity using cation exchange chromatography, image capillary isoelectric focusing (icIEF) or ca
  • Instability may involve any one or more of: aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomeriation), clipping/hydrolysis/fragmentation (e.g. hinge region fragmentation), succinimide formation, unpaired cysteine(s), /V-terminal extension, C-terminal processing, glycosylation differences, adduct formation etc.
  • deamidation e.g., Asn deamidation
  • oxidation e.g., Met oxidation
  • isomerization e.g., Asp isomeriation
  • clipping/hydrolysis/fragmentation e.g. hinge region fragmentation
  • succinimide formation unpaired cysteine(s)
  • /V-terminal extension e.g., C-terminal processing
  • glycosylation differences adduct formation etc.
  • a peptide "retains its physical stability” in a pharmaceutical composition or formulation if it shows no sign (or very little sign) of aggregation, precipitation and/or denaturation upon e.g. visual examination of colour and/or clarity, or as measured by UV light scattering, dynamic light scattering, circular dichroism, or by size exclusion chromatography and is considered to still retain its biological activity.
  • a peptide "retains its chemical stability” in a pharmaceutical composition or formulation, if the chemical stability at a given time is such that the peptide is considered to still retain its biological activity as defined below. Chemical stability can be assessed by detecting and quantifying chemically altered forms of the peptide.
  • Chemical alteration may involve isomerization, oxidation, size modification (e.g., clipping) which can be evaluated using HPLC or size exclusion chromatography, SDS-PAGE and/or mass spectrometry, for example.
  • Other types of chemical alteration include charge alteration (e.g., occurring as a result of deamidation) which can be evaluated by HPLC or ion-exchange chromatography or imaged capillary isoelectric focusing (icIEF), for example.
  • aqueous stable liquid pharmaceutical compositions of the present invention comprise dasiglucagon (or a pharmaceutically acceptable salt or solvate thereof as described above), a buffer, a tonicity modifier and are formulated to have a pH that is physiologically compatible with administration to a patient.
  • the stable aqueous liquid pharmaceutical compositions of the present invention further comprise a preservative, for example enabling multi-dose formulations to be produced.
  • compositions comprising dasiglucagon are described in detail in WO 2021/185821.
  • a formulation comprising dasiglucagon or a pharmaceutically acceptable salt and/or derivative thereof may comprise:
  • dasiglucagon or a pharmaceutically acceptable salt and/or derivative thereof present at a concentration of about 0.5 mg/mL to about 10 mg/mL, such as 4 mg/mL;
  • TRIS, Bis-TRIS, ACES or MES present as a buffer at a concentration of about 25 mM to about 75 mM, and/or citrate, acetate or succinate present as a buffer at a concentration of about 1 mM to about 30 mM;
  • liquid pharmaceutical compositions may comprise dasiglucagon or a pharmaceutically acceptable salt or solvate thereof in a concentration from about 0.01 mg/mL to about 25 mg/mL, such as from about 0.5 mg/mL to about 10 mg/mL, such as from about 1 mg/mL to about 10 mg/mL, e.g., from about 1 mg/mL to about 5 mg/mL.
  • a liquid pharmaceutical composition comprises dasiglucagon or a pharmaceutically acceptable salt or solvate thereof at a concentration of about 4 mg/mL.
  • the pH of the pharmaceutical composition is a pH selected from the list consisting of 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7,
  • the composition has a pH between about 5.6 to about 7.0, preferably between about 5.8 and 6.7, more preferably between about 6.0 and 6.8, and even more preferably a pH of about 6.5.
  • the pH may be adjusted using any means known in the art.
  • the pH is adjusted using hydrochloric acid (HCI) and/or sodium hydroxide (NaOH).
  • HCI hydrochloric acid
  • NaOH sodium hydroxide
  • the pharmaceutical composition of the invention may also comprise a buffer.
  • buffer as used herein denotes a pharmaceutically acceptable agent which stabilizes the pH of a pharmaceutical formulation.
  • the buffer or buffer substance is selected from the group consisting of: acetate buffers (e.g., sodium acetate), sodium carbonate, citrates (e.g., sodium citrate), glycylglycine, histidine, glycine, lysine, arginine, phosphates (e.g., chosen among sodium dihydrogen phosphate, disodium hydrogen phosphate and trisodium phosphate), TRIS (i.e., tris(hydroxymethyl)aminomethane), HEPES (i.e., 4-(2-hydroxyethyl)-l-piperazine- ethanesulfonic acid), BICINE (i.e., /V,/V-bis(2-hydroxyethyl)glycine), and TRICINE (i.e., N- [tris(hydroxymethyl)methyl]glycine), as well as succinate, malate, maleate, fumarate, tartrate, and aspart
  • any of these buffers are present at a concentration of about 1 mM to about 30 mM, more preferably about 10 mM to about 30 mM, and more preferably at a concentration of about 15 mM.
  • concentration used may take account of whether the buffers are used individually or in combination.
  • Some non-limiting preferred buffers in the context of the present invention are:
  • TRIS buffer ((tris(hydroxymethyl)aminomethane or 2-Amino-2-(hydroxymethyl)propane-l,3- diol) in IUPAC nomenclature);
  • Bis-TRIS buffer (Bis-Tris methane or 2-[Bis(2-hydroxyethyl)amino]-2- (hydroxymethyl)propane-l,3-diol) in IUPAC nomenclature);
  • ACES buffer ((/V-(2-Acetamido)-2-aminoethanesulfonic acid or 2- (carbamoylmethylamino)ethanesulfonic acid) in IUPAC nomenclature);
  • MES buffer (2-(N-morpholino)ethanesulfonic acid or as 2-morpholin-4-ylethanesulfonic acid in IUPAC nomenclature).
  • buffers that can be used as alternatives or in addition to these buffers include citrate, acetate or succinate, for example in the form of sodium citrate, sodium acetate or sodium succinate.
  • these buffers are present at a concentration of about 1 mM to about 30 mM, more preferably about 10 mM to about 30 mM, and more preferably at a concentration of about 15 mM.
  • the actual concentration used may take account of whether the buffers are used individually or in combination.
  • the composition comprises a pharmaceutically acceptable preservative.
  • preservatives include preservatives selected from the group consisting of: phenol, o-cresol, m-cresol, p-cresol, methyl p- hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, butyl p- hydroxybenzoate, 2-phenoxyethanol, 2-phenylethanol, benzyl alcohol, ethanol, chlorobutanol, thiomerosal, bronopol, benzoic acid, imidurea, chlorhexidine, sodium dehydroacetate, chlorocresol, benzethonium chloride, chlorphenesine [i.e., 3-(p- chlorphenoxy)propane-l,2-diol] and mixtures thereof.
  • preservatives selected from the group consisting of: phenol, o-cresol, m-cresol, p-cresol, methyl p- hydroxybenzoate, ethyl p-hydroxybenzoate, prop
  • Meta-cresol (m-cresol) is a preferred pharmaceutically acceptable preservative.
  • the preservative may be present in a concentration of from 0.1 mg/ml to 30 mg/ml, such as from 0.1 mg/ml to 20 mg/ml (e.g., from 0.1 mg/ml to 10 mg/ml, or from 2 mg/ml to 8 mg/ml, or from 4 mg/ml to 7 mg/ml) in the final liquid composition.
  • the preferred concentration is about 3.0 mg/ml to 4.0 mg/ml, e.g., about 3.15 mg/ml.
  • the preservative is meta-cresol at a concentration of about 1.0 mg/mL to about 5.0 mg/mL.
  • a pharmaceutical composition comprises a tonicity modifier.
  • tonicity modifier denotes pharmaceutically acceptable tonicity agents that are used to modulate the tonicity of the formulation.
  • the pharmaceutical compositions of the present invention are preferably isosmotic, that is they have an osmotic pressure that is substantially the same as human blood serum.
  • tonicity modifiers include agents selected from: salts (e.g., sodium chloride), sugars and sugar alcohols, amino acids (including glycine, arginine, lysine, isoleucine, aspartic acid, tryptophan and threonine), alditols (including glycerol, propyleneglycol (i.e., 1,2-propanediol), 1,3-propanediol and 1,3-butanediol), polyethylene glycols (including PEG400) and mixtures thereof.
  • salts e.g., sodium chloride
  • sugars and sugar alcohols include amino acids (including glycine, arginine, lysine, isoleucine, aspartic acid, tryptophan and threonine), alditols (including glycerol, propyleneglycol (i.e., 1,2-propanediol), 1,3-propanediol and
  • Suitable sugars include mono-, di- and polysaccharides, and water-soluble glucans, such as fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose sodium salt.
  • water-soluble glucans such as fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose sodium salt.
  • the tonicity modifier used in the pharmaceutical compositions is preferably sodium chloride.
  • the concentration of the tonicity modifier will be dependent on the concentration of other components of the pharmaceutical compositions, especially where the pharmaceutical compositions is intended to be isosmotic.
  • sodium chloride will be employed as a tonicity modifier at a concentration of about 50 mM to 600 mM.
  • the concentration of sodium chloride present as a tonicity modifier in the present pharmaceutical compositions may be from about 10 mM to about 150 mM, such as about 20 mM to about 130 mM, about 50 mM to about 125 mM, about 75 mM to about 120 mM, about 80 mM to about 100 mM, or about 90 mM.
  • the concentration of sodium chloride present as a tonicity modifier in the present pharmaceutical compositions may be from about 150 mM to about 200 mM, optionally about 175 mM.
  • sodium chloride may be present as a tonicity modifier in pharmaceutical compositions comprising a preservative at concentrations of about 50 mM to about 150 mM, and most preferably at a concentration of about 90 mM.
  • the stable aqueous liquid pharmaceutical composition of dasiglucagon (or a pharmaceutically acceptable salt or solvate thereof as described above) of the present invention preferably comprises:
  • TRIS, Bis-TRIS, ACES or MES present as a buffer at a concentration of about 50 mM
  • the present invention provides dasiglucagon (and pharmaceutically acceptable salts or solvates thereof), as well as pharmaceutical compositions as described above comprising the same for use in the treatment and/or prevention of a variety of conditions or disorders, in particular hypoglycaemia, such as nocturnal hypoglycaemia, more particular CHI.
  • the compounds (and pharmaceutically acceptable salts or solvates thereof) may be used in combination with one or more additional therapeutically active substances.
  • the present invention provides the use of dasiglucagon (and pharmaceutically acceptable salts or solvates thereof), as well as pharmaceutical compositions comprising the same in a method for treating and/or preventing hypoglycaemia, such as nocturnal hypoglycaemia, more particularly CHI.
  • the present invention provides methods for treating and/or preventing hypoglycaemia, such as nocturnal hypoglycaemia, more particularly CHI.
  • hypoglycaemia such as nocturnal hypoglycaemia, more particularly CHI.
  • the present invention thus provides dasiglucagon (and pharmaceutically acceptable salts or solvates thereof), as well as pharmaceutical compositions comprising the same in the manufacture of a medicament for the treatment and/or prevention of hypoglycaemia, such as nocturnal hypoglycaemia, more particularly CHI.
  • the present invention also provides dasiglucagon (and pharmaceutically acceptable salts or solvates thereof), as well as pharmaceutical compositions comprising the same for use in the treatment and/or prevention of hypoglycaemia, such as nocturnal hypoglycaemia, more particularly CHI, wherein the patient is suffering from NME (necrolytic migratory erythema).
  • hypoglycaemia such as nocturnal hypoglycaemia, more particularly CHI
  • NME non-lytic migratory erythema
  • the hypoglycaemia is nocturnal hypoglycaemia.
  • the hypoglycaemia is CHI.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME).
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of CHI, in a patient suffering from necrolytic migratory erythema (NME).
  • NME necrolytic migratory erythema
  • a further aspect of the invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of nocturnal hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME).
  • NME necrolytic migratory erythema
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising reducing the dose of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of CHI, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising reducing the dose of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of nocturnal hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising reducing the dose of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising reducing the infusion rate of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of CHI, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising reducing the infusion rate of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of nocturnal hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising reducing the infusion rate of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising discontinuing the treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • the hypoglycaemia is nocturnal hypoglycaemia.
  • the hypoglycaemia is CHI.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising interrupting the treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • the dose may be interrupted for a period of for example 1-2 days, 1-3 days, 1-4 days, 1-5 days, 1-6 days or 1-7 days or more than 7 days.
  • the hypoglycaemia is nocturnal hypoglycaemia.
  • the hypoglycaemia is CHI.
  • a further aspect of the invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising reducing the dose of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • the hypoglycaemia may be nocturnal hypoglycaemia.
  • An additional aspect of the invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising discontinuing the infusion of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • the hypoglycaemia may be nocturnal hypoglycaemia.
  • a further aspect of the invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention of hypoglycaemia, in a patient suffering from necrolytic migratory erythema (NME) by a dosage regimen comprising interrupting the dose of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • the dose may be interrupted for a period of for example 1-2 days, 1-3 days, 1-4 days, 1-5 days, 1-6 days, 1-7 days or more than 7 days.
  • the hypoglycaemia may be nocturnal hypoglycaemia.
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating and/or preventing hypoglycaemia, wherein the method comprises the following steps:
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating congenital hyperinsulinism (CHI), wherein the method comprises the following steps:
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating and/or preventing nocturnal hypoglycaemia, wherein the method comprises the following steps:
  • treatment refers to an approach for preventing and/or for obtaining beneficial or desired clinical results.
  • beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilization of (i.e., not worsening of) state of disease, delay or slowing of disease progression, amelioration or palliation of disease state, and remission (whether partial or total), whether detectable or undetectable.
  • Treatment may also refer to prolongation of survival compared to expected survival in the absence of treatment.
  • Treatment is an intervention performed with the intention of preventing the development of, or altering the pathology of, a disorder. Accordingly, “treatment” refers both to therapeutic treatment and to prophylactic or preventative measures. As used in the context of prophylactic or preventative measures, the pharmaceutical formulation need not completely prevent the development of the disease or disorder. Those in need of treatment include those already suffering from the disorder, as well as those in which development of the disorder is to be prevented. “Treatment” also means inhibition or reduction of an increase in pathology or symptoms (e.g., weight gain or hypoglycaemia) compared to the absence of treatment and is not necessarily meant to imply complete cessation of the relevant condition.
  • pathology or symptoms e.g., weight gain or hypoglycaemia
  • dasiglucagon and pharmaceutically acceptable salts or solvates thereof, as well as pharmaceutical compositions or formulations comprising the same, may be useful to control blood glucose levels, in particular during long periods of time, such as for example 3 or more hours, or 4 or more hours, or 5 or more hours, or 6 or more hours, or 7 or more hours, or 8 or more hours, or 9 or more hours, or 10 or more hours, preferably during periods of time or more than 6 hours, such as about 6 hours, or more than 7 hours, such as about 7 hours, or more than 8 hours, such as one day, or more, such as 2 days, or 3 days, or 4 days, or 5 days, or 6 days, or 7 days, or more, such as 2 weeks, or 3 weeks, or 4 weeks, or 5 weeks, or 6 weeks, or 7 weeks, or 8 weeks, or three months, or five months, or six months, or one year, or more.
  • patient may be used interchangeably in the context of the present invention, and refer to either a human or a non-human animal.
  • mammals such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).
  • the patient is a human, more particularly a newborn or a child.
  • the patient is 12 years (inclusive) or younger. In another embodiment, the patient is under 12 months (exclusive) of age.
  • the patient is 7 days (inclusive) or older. In another embodiment the patient is 3 months (inclusive) or older.
  • the patient is between the ages of 3 months and 12 years (both inclusive).
  • the patients have a weight at the beginning of the treatment, i.e., at baseline, of 20 kg or less, more preferably the patients have a weight at the beginning of the treatment, i.e., at baseline, of 10 kg or more but less than 20 kg.
  • the patients have a weight of less than 10 kg, optionally of between 5 (inclusive) and 10 (exclusive) kg.
  • the patient is between the ages of 3 months and 12 years (both inclusive and has a bodyweight of between 5 (inclusive) and 10 (exclusive) kg.
  • the patient has not had a pancreatectomy before the start of the treatment.
  • pancreatectomy refers to surgical removal of all or part of the pancreas.
  • the patient has an ABCC8 mutation.
  • ABCC8 gene ATP Binding Cassette Subfamily C Member 8, Gene ID: 6833, updated on 4-Dec- 2023
  • the protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters.
  • ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White).
  • This protein is a member of the MRP subfamily which is involved in multi-drug resistance. This protein functions as a modulator of ATP-sensitive potassium channels and insulin release. Mutations and deficiencies in this protein have been observed in patients with hyperinsulinemic hypoglycemia of infancy, an autosomal recessive disorder of unregulated and high insulin secretion. Mutations have also been associated with non-insulin-dependent diabetes mellitus type II (neonatal diabetes), an autosomal dominant disease of defective insulin secretion, and congenital hyperinsulinism.
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of hypoglycaemia, in a patient with an ABCC8 mutation.
  • the hypoglycaemia may be nocturnal hypoglycaemia.
  • the hypoglycaemia is CHI.
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of CHI, in a patient with an ABCC8 mutation.
  • An additional aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention of hypoglycaemia, in a patient with an ABCC8 mutation.
  • the hypoglycaemia may be nocturnal hypoglycaemia.
  • the hypoglycaemia is CHI.
  • the ABCC8 mutation may be a homozygous mutation, a heterozygous mutation or an unknown ABCC8 mutation type. In one aspect the ABCC8 mutation is a heterozygous mutation.
  • the mutation is a change in an amino acid of the protein sequence of the ABCC8 gene. In another aspect the mutation changes a single amino acid in the SURI protein coded by the ABCC8 gene.
  • terapéuticaally effective amount and “therapeutically effective dose” as employed in the context of the present invention refer to an amount or a dose sufficient to cure, alleviate, partially arrest or otherwise promote the cure or healing of a given condition (disorder, disease) or injury and, preferably, complications arising therefrom.
  • An amount or dose effective for a particular purpose will depend on the severity of the condition or injury as well as on the body weight and general state of the subject or patient to be treated. Determination of an amount or dose that is appropriate is within the skills of a trained physician (or veterinarian) of ordinary skill.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI.
  • the invention relates to a method for treating CHI comprising administering the compound or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition of the invention to a subject in need thereof, as described above.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating nocturnal hypoglycaemia in CHI patients
  • the invention relates to a method for treating nocturnal hypoglycaemia in CHI patients comprising administering the compound or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition of the invention to a subject in need thereof, as described above.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI and the treatment reduces the percent time in hypoglycaemia, wherein the percent time in hypoglycaemia is defined as the percent time that the patient has a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L), measured by continued glucose monitoring (CGM).
  • CGM continued glucose monitoring
  • the invention relates to a method for treating CHI comprising administering dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition of the invention to a subject in need thereof and the treatment reduces the percent time in hypoglycaemia as compared with the percent time in hypoglycaemia in patients receiving the standard of care (SoC) treatment, wherein the percent time in hypoglycaemia is defined as the percent time that the patient has a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L), measured by CGM.
  • SoC standard of care
  • the treatment reduces the mean percent time in hypoglycaemia during weeks 2-4 by at least 10%, 20%, 30%, or 40%, or more, such as at least 41%, relative to the percent time in hypoglycaemia in patients receiving the SoC treatment.
  • the mean percent time in hypoglycaemia during weeks 2-4 is reduced by at least 10 - 50%, 20 - 45%, or 30 - 41% relative to the percent time in hypoglycaemia in patients receiving the SoC treatment.
  • the mean percent time in hypoglycaemia during weeks 2-4 is reduced by at least 41% relative to the percent time in hypoglycaemia in patients receiving the SoC treatment. In another embodiment.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI, and the treatment reduces the rate of hypoglycaemic episodes.
  • the rate of hypoglycaemic episodes can be defined as the number of CGM-detected episodes per week.
  • a single CGM-detected hypoglycaemic episode is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L) measured by CGM for 15 minutes and up until 60 minutes from the start of the episode even if normoglycemia (>70 mg/dL or >3.9 mmol/L) was not reached within this time, wherein a new episode of hypoglycaemia begins when the next CGM values below 70 mg/dL (or below 3.9 mmol/L) was measured for at least 15 minutes.
  • the invention relates to a method for treating CHI comprising administering the dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition of the invention to a subject in need thereof and the treatment reduces the rate of hypoglycaemic episodes, wherein the rate of hypoglycaemic episodes is defined as the number of CGM-detected episodes per week, wherein a single CGM-detected hypoglycaemia episode is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L) measured by CGM for 15 minutes and up until 60 minutes from the start of the episode even if normoglycemia (>70 mg/dL or >3.9 mmol/L) is not reached within this time, and a new episode of hypoglycaemia begins when the next CGM value below 70 mg/dL or below 3.9 mmol/L is measured for at least 15 minutes.
  • the rate of hypoglycaemic episodes is defined as the number of CGM-detected episodes per week
  • the treatment reduces the mean rate of hypoglycaemic episodes during weeks 2-4 of treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein, is reduced by at least 10% such as by at least 20% or, or by at least 30%, or by at least 35%, such as by at least 40%, or more, such as by at least 41% or by at least 42.5%, such by at least 42.9%, or at least about 43%, relative to the mean rate of hypoglycaemic episodes in patients receiving the SoC treatment.
  • the mean rate of hypoglycaemic episodes during weeks 2-4 is reduced by at least 10 - 60%, 20 - 50%, or 35 - 45 % relative to the mean rate of hypoglycaemic episodes in patients receiving the SoC treatment.
  • the mean rate of hypoglycaemic episodes during weeks 2-4 is reduced by at least 40%, preferably by at least 41%, or at least 42.5%, such by at least 42.9%, or at least about 43%, relative to the mean rate of hypoglycaemic episodes in patients receiving the SoC treatment.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is administered at a dose of at least 10 pg/h.
  • the amount of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same may preferably be increased by 10 pg/h every two hours, to a maximum of 70 pg/h, see below section "Dosage and schedule" for further details.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI, and the treatment reduces the percent time in clinically significant hypoglycaemia, wherein the percent time in clinically significant hypoglycaemia is defined as the percent time that the patient has a glucose level of ⁇ 54 mg/dL measured by CGM.
  • the invention relates to a method for treating CHI comprising administering dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same to a subject in need thereof, and the treatment reduces the percent time in clinically significant hypoglycaemia, wherein the percent time in clinically significant hypoglycaemia is defined as the percent time that the patient has a glucose level of ⁇ 54 mg/dL measured by continued glucose monitoring (CGM).
  • CGM continued glucose monitoring
  • the treatment reduces the mean percent time in clinically significant hypoglycaemia during weeks 2-4 of treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein, by at least 10%, such by as at least 20%, or by at least 30%, or by at least 40%, such as by at least 45%, or by at least about 48%, relative to the mean percent time in clinically significant hypoglycaemia in patients receiving the SoC treatment.
  • the mean percent time in clinically significant hypoglycaemia during weeks 2-4 of treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein is reduced by at least 10 - 70%, such as by at least20 - 60%, or by at least 30 - 50%, such as by at least 45 - 50% relative to the mean percent time in clinically significant hypoglycaemia in patients receiving the SoC treatment.
  • the mean percentage time in clinically significant hypoglycaemia during weeks 2-4 is reduced by at least 45%, preferably by at least 48%relative to the mean percent time in clinically significant hypoglycaemia in patients receiving the SoC treatment.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is administered at a dose of at least 10 pg/h.
  • the amount of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same may preferably be increased by 10 pg/h every two hours, to a maximum of 70 pg/h, see below section "Dosage and schedule" for further details.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI and the treatment reduces the rate of clinically significant hypoglycaemic episodes.
  • the rate of clinically significant hypoglycaemic episodes is defined as the number of CGM -detected episodes per week.
  • a single CGM -detected clinically significant hypoglycaemic episode is defined as a glucose level of ⁇ 54 mg/dL measured by CGM for 15 minutes and up until 60 minutes from the start of the episode, even if normoglycemia (>70 mg/dL) is not reached within this time.
  • a new episode of clinically significant hypoglycaemia begins when the next CGM values below 54 mg/dL is measured for at least 15 minutes.
  • the invention relates to a method for treating CHI comprising administering the compound or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition of the invention to a subject in need thereof and the treatment reduces the rate of clinically significant hypoglycaemic episodes.
  • the rate of clinically significant hypoglycaemic episodes is defined as the number of CGM-detected episodes per week.
  • a single CGM- detected clinically significant hypoglycaemic episode is defined as a glucose level of ⁇ 54 mg/dL measured by CGM for 15 minutes and up until 60 minutes from the start of the episode even if normoglycemia (>70 mg/dL) is not reached within this time.
  • a new episode of clinically significant hypoglycaemia begins when the next CGM values below 54 mg/dL is measured for at least 15 minutes.
  • the treatment reduces the mean rate of clinically significant hypoglycaemic episodes during weeks 2-4 of treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein, by at least 10%, such as by at least 20% or by at least 30%, such as by at least 40%, e.g., at least 41.5%, relative to the mean rate of clinically significant hypoglycaemic episodes during weeks 2-4 in patients receiving the SoC treatment.
  • the mean rate of clinically significant hypoglycaemic episodes during weeks 2-4 is reduced by at least 10 - 60%, such as by at least 20 - 50%, or by at least 35 - 45% relative to the mean rate of clinically significant hypoglycaemic episodes during weeks 2-4 in patients receiving the SoC treatment.
  • the mean rate of clinically significant hypoglycaemic episodes during weeks 2-4 is reduced by at least 40%, more preferably by at least 41%, such as by at least 41.5%, relative to the mean rate of clinically significant hypoglycaemic episodes during weeks 2-4 in patients receiving the SoC treatment.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is administered at a dose of at least 10 pg/h.
  • the amount of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same may preferably be increased by 10 pg/h every two hours, to a maximum of 70 pg/h, see below section "Dosage and schedule" for further details.
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating hypoglycaemia, wherein the treatment reduces the glucose infusion rate (mg/kg/min) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI, wherein the treatment reduces the glucose infusion rate (mg/kg/min) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating nocturnal hypoglycemia, wherein the treatment reduces the glucose infusion rate (mg/kg/min) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of preventing hypoglycaemia, wherein the treatment reduces the glucose infusion rate (mg/kg/min) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of preventing nocturnal hypoglycemia, wherein the treatment reduces the glucose infusion rate (mg/kg/min) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating hypoglycaemia, wherein the treatment reduces the total amount of carbohydrates administered per day (g/day) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI, wherein the treatment reduces the total amount of carbohydrates administered per day (g/day) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating nocturnal hypoglycemia, wherein the treatment reduces the total amount of carbohydrates administered per day (g/day) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of preventing hypoglycaemia, wherein the treatment reduces the total amount of carbohydrates administered per day (g/day) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • a further aspect of the present invention is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of preventing nocturnal hypoglycemia, wherein the treatment reduces the total amount of carbohydrates administered per day (g/day) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • the carbohydrates administered per day are administered by IV infusion, nasogastric tube, gastrostomy, or the oral route.
  • the carbohydrate is administered via the oral route.
  • the carbohydrate administered via the oral route may be administered in any form, for example as a solid composition, as a liquid composition, or as a gel composition.
  • the carbohydrate comprises one or more sugars selected from the group comprising glucose, sucrose and fructose.
  • the SoC can include most drugs commonly used and/or recommended in treatment of CHI including, but not limited to: application of carbohydrate-rich liquids mainly via NG-tube or gastric infusions, carbohydrate fortification of other feeds (including oral), diazoxide treatment, and somatostatin analogues (e.g., octreotide, octreotide LAR, or lanreotide), including somatostatin.
  • somatostatin analogues e.g., octreotide, octreotide LAR, or lanreotide
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as disclosed herein is provided for use in a method of treating nocturnal hypoglycaemia in CHI patients.
  • the invention relates to a method for treating nocturnal hypoglycaemia in CHI patients, the method comprising administering the compound or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition of the invention to a subject in need thereof (to a CHI subject).
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is provided for use in a method of treating CHI, and the treatment reduces nocturnal hypoglycaemia.
  • "Nocturnal hypoglycaemia" has been described in the present description.
  • the invention relates to a method for treating CHI comprising administering dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same to a subject in need thereof (CHI patient), and the treatment reduces nocturnal hypoglycaemia.
  • the mean number of nocturnal hypoglycaemic episodes is defined as the mean number of CGM-detected hypoglycaemic episodes/week with onset between 10 pm (excluded) and 6 am (excluded), wherein a single CGM-detected hypoglycaemic episode is defined as CGM ⁇ 3.9 mmol/L for 15 minutes and up until 60 minutes from the start of the episode, even if normoglycemia (>3.9 mmol/L) is not reached within this time.
  • a new hypoglycaemic episode is defined when the next CGM value below 3.9 mmol/L for at least 15 min is detected.
  • the mean number of nocturnal hypoglycaemic episodes is defined as the mean number of CGM-detected hypoglycaemic episodes/week with onset between 10 pm (excluded) and 6 am (excluded), wherein a single CGM-detected hypoglycaemic episode is defined as CGM ⁇ 3.0 mmol/L for 15 minutes and up until 60 minutes from the start of the episode, even if normoglycemia (>3.9 mmol/L) is not reached within this time.
  • a new hypoglycaemic episode is defined when the next CGM value below 3.0 mmol/L for at least 15 min is detected.
  • the method of the present invention reduces the mean number of nocturnal hypoglycaemic episodes by at least 30%, or by at least 40%, or by at least 45%, or by at least 48%, such as by at least 50%, preferably by at least 48%, wherein the mean number of nocturnal hypoglycaemic episodes is defined as the episodes/week with onset between 10 pm (excluded) and 6 am (excluded), wherein a single CGM-detected hypoglycaemic episode is defined as CGM ⁇ 3.9 mmol/L for 15 minutes and up until 60 minutes from the start of the episode, even if normoglycemia (>3.9 mmol/L) is not reached within this time.
  • a new hypoglycaemic episode is defined when the next CGM value below 3.9 mmol/L for at least 15 min is detected.
  • CHI congenital hyperinsulinism
  • Current standard medical treatment of congenital hyperinsulinism could include most drugs commonly used and/or recommended in treatment of CHI including, but not limited to: application of carbohydrate-rich liquids mainly via NG-tube or gastric infusions, carbohydrate fortification of other feeds (including oral), diazoxide treatment, and somatostatin analogues (e.g., octreotide, octreotide LAR, or lanreotide), including somatostatin.
  • carbohydrate-rich liquids mainly via NG-tube or gastric infusions
  • carbohydrate fortification of other feeds including oral
  • diazoxide treatment e.g., diazoxide treatment
  • somatostatin analogues e.g., octreotide, octreotide LAR, or lanreotide
  • the patient receives the same standard of care before and during the treatment with the compound or pharmaceutical compositions of the invention.
  • the standard of care can also continue on after the treatment.
  • this application will refer to other therapies that have been carried out before, during or after therapy with the compound of the invention (dasiglucagon) as standard of care or combination therapy.
  • dasiglucagon the compound of the invention
  • a non-conclusive list of further substances that patients may receive before, during or after treatment with the compound of the invention (dasiglucagon) is described hereinbelow.
  • Diazoxide sold under the brand name Proglycem, is a medication used to treat low blood sugar due to a number of specific causes. Diazoxide has a structure as depicted below:
  • Octreotide sold under the brand name Sandostatin is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone, is depicted below:
  • Sirolimus also known as rapamycin and sold under the brand name Rapamune among others, has the structure depicted below:
  • pharmacologically active substances or agents used as a standard of care in connection with CHI are, for example antidiabetic agents, antiobesity agents, appetite-regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes, and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • antidiabetic agent includes compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pathophysiological mechanism.
  • examples of such pharmacologically active substances are insulin and insulin analogues, GLP- 1 agonists, sulfonylureas (e.g.
  • tolbutamide glibenclamide, glipizide and gliclazide
  • biguanides e.g. metformin
  • meglitinides e.g. acarbose
  • glucagon antagonists e.g. dipeptidyl peptidase IV (DPP-IV) inhibitors
  • DPP-IV dipeptidyl peptidase IV
  • inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis glucose uptake modulators, thiazolidinediones such as troglitazone and ciglitazone
  • compounds modifying the lipid metabolism such as antihyperlipidemic agents (e.g.
  • HMG CoA inhibitors compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potassium channel of the p-cells, e.g. glibenclamide, glipizide, gliclazide and repaglinide; cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine, neteglinide, repaglinide; p-blockers, such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, alatriopril, quinapril and rami
  • the CHI patient has not been treated with diazoxide as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • the patient has never been treated with diazoxide before the treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same.
  • patients who have not received diazoxide at baseline i.e., before treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein, respond particularly well to treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same.
  • the patient has received a somatostatin analogue as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • a somatostatin analogue as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • the somatostatin analogues can be any or a combination of those listed above.
  • somatostatin analogue refers to both analogues of somatostatin as outlined above and known in the art, as well as native somatostatin (somatostatin).
  • the patient has received diazoxide as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • diazoxide as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • the administration of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is performed together with diazoxide, i.e., dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is co-administered together with diazoxide.
  • the patient has received glucagon as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • glucagon it is preferred that treatment with glucagon continues during the treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • the administration of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is performed together with glucagon, i.e., dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is co-administered together with glucagon.
  • the patient has received sirolimus as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • sirolimus it is preferred that treatment with sirolimus continues during the treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • the administration of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is performed together with sirolimus, i.e., dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is co-administered together with sirolimus.
  • the patient has received at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus as the standard of care before the treatment, i.e., at baseline, with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • treatment with at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus continues during the treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein.
  • the administration of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is performed together with at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus, i.e., dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same is co-administered together with at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus.
  • the patients have not had a total pancreatectomy before the start of the treatment.
  • the patients have not had any pancreatectomy, i.e., "sub-total", “near-total” or “total” pancreatectomy, before the start of the treatment.
  • Total pancreatectomy involves the removal of the entire pancreas.
  • Sub-total pancreatectomy may involve the removal of 95% or less than 95% of the pancreas.
  • Near-total pancreatectomy can be defined as the removal of more than 95% of the pancreas.
  • Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and/or pharmaceutical compositions comprising the same may be administered to a patient in need of such treatment at various sites, for example administration at sites which bypass absorption, such as in an artery or vein or in the heart, and at sites which involve absorption, such as in the skin, under the skin, in a muscle or in the abdomen.
  • administration may be performed by a variety of routes, such as or example parenteral, epidermal, dermal or transdermal routes.
  • routes such as or example parenteral, epidermal, dermal or transdermal routes.
  • other routes such as lingual, sublingual, buccal, oral, vaginal or rectal may be useful.
  • administration of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein is performed by parenteral administration, for example, by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, suitably a pen-like syringe.
  • Subcutaneous administration is preferred.
  • Administration can take place by means of an infusion pump, e.g., in the form of a device or system borne by a subject or patient and comprising a reservoir containing a liquid composition of the invention and an infusion pump for delivery/administration of the composition to the subject or patient, or in the form of a corresponding miniaturized device suitable for implantation within the body of the subject or patient.
  • an infusion pump e.g., in the form of a device or system borne by a subject or patient and comprising a reservoir containing a liquid composition of the invention and an infusion pump for delivery/administration of the composition to the subject or patient, or in the form of a corresponding miniaturized device suitable for implantation within the body of the subject or patient.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and/or pharmaceutical compositions comprising the same may be administered in various dosage forms, for example solutions, suspensions or emulsions, and are useful in the formulation of controlled-, sustained-, protracted-, retarded- or slow-release drug delivery systems.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and/or pharmaceutical compositions comprising the same may be administered continuously.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and/or pharmaceutical compositions comprising the same is administered at a dose of at least 10 pg/h, such as a dose of at least 15 pg/h, or at a dose of at least 20 pg/h, or at a dose of at least 25 pg/h, or at a dose of at least 30 pg/h, or at a dose of at least 40 pg/h, or at a dose of at least 50 pg/h, or at a dose of at least 55 pg/h, or at a dose of at least 60 pg/h, orat a dose of at least 65 pg/h, orat a dose of at least 70 pg/h, such as a dose of about 70 pg/h.
  • a dose of at least 10 pg/h such as a dose of at least 15 pg/h, or at a dose of at least 20 pg/h, or at
  • Adverse events emerged that were considered to be related to dasiglucagon (e.g., nausea and vomiting) and limited further dose escalation.
  • the dose is increased by 10 pg/h every two hours from the start of treatment to a maximum dose of 70 pg/h. In case any of the above situations (i) to (iii) occur, the dose is not further increased.
  • the dose of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein administrated to a patient is between 10 - 70 pg/h, such as between 20 - 70 pg/h, or between 30 - 70 pg/h, or between 40 - 70 pg/h, or between 50 - 70 pg/h, between 60 - 70 pg/h.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein is administered to a patient for at least two weeks, such as for two weeks, or for at least three weeks, such as for three weeks, or for at least four weeks, such as for about four weeks, or for at least five weeks, such as for about five weeks, or for at least six weeks, such as for about six weeks, or for at least seven weeks, such as for about seven weeks, or for at least eight weeks, such as for about eight weeks, or more, such as for 9, 10, 15, 20, 30, 40, 50, 60 or 100 weeks or more.
  • treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and/or pharmaceutical compositions comprising the same may take place in combination with one or more further known therapies against CHI (e.g., included in the standard of care as defined above above).
  • Any suitable combination of a compound or compounds according to the invention with one or more of the above-mentioned compounds, and optionally one or more further pharmacologically active substances, is within the scope of the present invention.
  • the patient continues to receive any or a combination of the therapies they received before the start of the treatment, i.e., at baseline, referred to above as standard of care.
  • the administration of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, as defined herein is concomitant with the standard of care.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and a somatostatin analogue for use in a method of treating hypoglycemia.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and a somatostatin analogue for use in a method of treating CHI is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and a somatostatin analogue for use in a method of treating CHI.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and a somatostatin analogue for use in a method of treating nocturnal hypoglycemia is dasiglucagon or a pharmaceutically acceptable salt or solvate thereof and a somatostatin analogue for use in a method of treating nocturnal hypoglycemia.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating hypoglycemia, wherein the patient has previously been treated with a somatostatin analogue, such as where the patient is undergoing treatment with a somatostatin analogue at the onset of treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating CHI, wherein the patient has previously been treated with a somatostatin analogue, such as where the patient is undergoing treatment with a somatostatin analogue at the onset of treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating nocturnal hypoglycemia, wherein the patient has previously been treated with a somatostatin analogue, such as where the patient is undergoing treatment with a somatostatin analogue at the onset of treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • Said somatostatin analogue may include somatostatin, octreotide and lanreotide.
  • Item 1 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating and/or preventing hypoglycaemia.
  • Item 2 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating and/or preventing nocturnal hypoglycaemia.
  • Item 3 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating congenital hyperinsulinism (CHI).
  • CHI congenital hyperinsulinism
  • Item 4 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method according to any of the preceding items, wherein Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof is provided in a composition together with at least one pharmaceutically acceptable excipient.
  • Item 5 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the treatment reduces the percentage time in hypoglycaemia, wherein the percent time in hypoglycaemia is defined as a glucose level of ⁇ 70 mg/dL measured by continued glucose monitoring (CGM), optionally wherein the mean percentage time in hypoglycaemia during weeks 2-4 is reduced by at least 41% relative to the percent time in hypoglycaemia in patients receiving the SoC treatment.
  • CGM continued glucose monitoring
  • Item 6 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the treatment reduces the rate of hypoglycaemic episodes, wherein the rate of hypoglycaemic episodes is defined as the number of CGM-detected episodes per week, wherein a single CGM-detected hypoglycaemic episode is defined as a glucose level of ⁇ 70 mg/dL measured by continued glucose monitoring (CGM) for 15 minutes and up until 60 minutes from the start of the episode even if normoglycemia (>70 mg/dL) was not reached within this time, wherein a new episode of hypoglycaemia begins when the next CGM values below 70 mg/dL was measured for at least 15 minutes, optionally wherein the mean rate of CGM-detected hypoglycaemic episodes during weeks 2-4 is reduced by at least 41% relative to the mean rate of CGM-detected hypoglycaemic episodes in patients receiving the SoC treatment.
  • CGM
  • Item 7. Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the treatment reduces the percentage time in clinically significant hypoglycaemia, wherein the percent time in clinically significant hypoglycaemia is defined as a glucose level of ⁇ 54 mg/dL measured by CGM, optionally wherein the mean percentage time in clinically significant hypoglycaemia during weeks 2-4 is reduced by at least 48% relative to the mean percentage time in clinically significant hypoglycaemia in patients receiving the SoC treatment.
  • Item 9 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the patient has a body weight of 5 to ⁇ 10 kg at the start of the treatment.
  • Item 10 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any one of the preceding items, wherein the method does not comprise administration of diazoxide, optionally wherein the patient has never been treated with diazoxide.
  • Item 11 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any one of the preceding items, wherein the method does not comprise administration of diazoxide and wherein the patient has never been treated with diazoxide.
  • Item 12 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method additionally comprises coadministration of at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus, optionally wherein the patient has previously been treated with at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus.
  • Item 13 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method additionally comprises coadministration of at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus, wherein the patient has previously been treated with at least one of diazoxide, a somatostatin analogue, glucagon and/or sirolimus.
  • Item 14 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method additionally comprises coadministration of a somatostatin analogue, optionally wherein the patient has previously been treated with a somatostatin analogue.
  • Item 15 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method additionally comprises coadministration of a somatostatin analogue, wherein the patient has previously been treated with a somatostatin analogue.
  • Item 16 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method additionally comprises coadministration of somatostatin, optionally wherein the patient has previously been treated with somatostatin.
  • Item 17 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method additionally comprises coadministration of somatostatin, wherein the patient has previously been treated with somatostatin.
  • Item 18 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the patient has not had a pancreatectomy before the start of the treatment.
  • Item 19 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the patient has an ABCC8 mutation.
  • Item 20 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the patient has a homozygous ABCC8 mutation.
  • Item 21 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the patient has a heterozygous ABCC8 mutation.
  • Item 22 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the patient has an unknown ABCC8 mutation.
  • Item 23 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in a method according to any of the preceding items, wherein the method reduces nocturnal hypoglycaemia.
  • Item 24 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method reduces the mean number of nocturnal hypoglycaemic episodes by at least 50%, wherein the mean number of nocturnal hypoglycaemic episodes is defined as the episodes/week with onset between 10 pm and 6 am, wherein a single CGM-detected hypoglycaemic episode is defined as CGM ⁇ 3.9 mmol/L for 15 minutes and up until 60 minutes from the start of the episode even if normoglycemia (>3.9 mmol/L) is not reached within this time, a new hypoglycaemic episode is defined as when the next CGM value was below 3.9 mmol/L for at least 15 min, optionally wherein the method reduces the mean number of nocturnal hypoglycaemic episodes by at least 48%, wherein the mean number of nocturnal hypoglycaemic episodes is defined as the episodes/week with onset between
  • Item 25 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method reduces the glucose infusion rate (mg/kg/min) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • Item 26 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method reduces the total amount of carbohydrates administered per day (g/day) required to avoid hypoglycemia, wherein hypoglycemia is defined as a glucose level of ⁇ 70 mg/dL (or ⁇ 3.9 mmol/L).
  • Item 27 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to item 26, wherein the carbohydrates administered per day (g/day) are administered by IV infusion, nasogastric tube, gastrostomy, or by the oral route, preferably wherein the carbohydrates are administered via the oral route.
  • Item 28 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to item 27, wherein the carbohydrates administered via the oral route are administered as a solid composition, as a liquid composition, or as a gel composition.
  • Item 29 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any one of items 26 to 28 wherein the carbohydrate comprises a carbohydrate selected from the group comprising a monosaccharide, a disaccharide, a polyol, an oligosaccharides and a polysaccharide.
  • Item 30 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any one of items 26 to 29, wherein the carbohydrate comprises one or more sugars selected from the group comprising glucose, sucrose and fructose.
  • Item 31 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method comprises treatment with dasiglucagon for 4 or 8 weeks, optionally wherein treatment with the standard of care is concomitant.
  • Item 32 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein dasiglucagon is administered at a dose of at least 10 pg/h, optionally wherein the dose is increased by 10 pg/h every two hours from the start of treatment to a maximum dose of 70 pg/h, optionally wherein dasiglucagon is administered at a dose of 70 pg/h.
  • Item 33 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any one of the preceding items, wherein the method of treatment is used in paediatric patients, optionally wherein the patients are between 3 months and 12 years of age.
  • Item 34 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any one of the preceding items, wherein the method of treatment is used in a patient suffering from NME (necrolytic migratory erythema).
  • Item 35 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to item 34, wherein the method of treatment comprises reducing the dose of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • Item 36 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to item 34, wherein the method of treatment comprises reducing the infusion rate of dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • Item 37 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to item 34, wherein the method of treatment comprises discontinuing treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • Item 38 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to item 34, wherein the method of treatment comprises interrupting treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof.
  • Item 39 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to item 38, wherein treatment with dasiglucagon or a pharmaceutically acceptable salt or solvate thereof is interrupted for a period of 1-2 days, 1-3 days, 1-4 days, 1-5 days, 1-6 days or 1-7 days.
  • Item 40 Dasiglucagon or a pharmaceutically acceptable salt or solvate thereof for use in the method according to any of the preceding items, wherein the method comprises the following steps:
  • the glucagon analogues used in the formulations of the present invention can be synthesized using solid phase peptide synthesis techniques well known in the art. By way of example, this may be carried out on a CEM Liberty Peptide Synthesizer using Tentagel S PHB-Thr(tBu) resin (1.13 g, 0.24 mmol/g), COMU as coupling reagent, DMF as the solvent, and Fmoc-chemistry as described above. Pseudoprolines Fmoc-Phe-Thr (MJ Me, Me pro)-OH (in position 6/7) and Fmoc-Glu-Ser (MJ, Me, Me pro)-OH (in position 15/16) were used in the sequence.
  • the glucagon analogue may be cleaved from the resin, and the purification was performed on a Gemini-NX column (5 cm, C18, 10 micron) with a 35 ml/min flow of a mixture of buffer A (0.1% aqueous TFA) and buffer B (aqueous solution containing 0.1% TFA and 90% MeCN). Pooled fractions may be lyophilized and re-dissolved in water prior to further purification. The purity of the product may be determined by analytical HPLC and the monoisotopic mass determined by MS.
  • CHI congenital hyperinsulinism
  • Enrolled patients were male or female, >7 days to ⁇ 12 months of age at screening, with a body weight of >2.0 kg (4.4 lbs), and a diagnosis of CHI based on presence of the following: hyperinsulinemia, hypofattyacidemia, hypoketonemia, and/or glycemic response.
  • Exclusion criteria were reviewed at trial entry and before randomization. Patients who were suspected of having a transient form of CHI, born preterm below 34 weeks of gestational age, or with known or suspected brain damage were excluded at trial entry. Patients with hypertension or hypotension, or with metabolic, endocrine, or syndromic causes of hypoglycemia not due to hyperinsulinism were also excluded at trial entry. Additional exclusion criteria were evaluated at the time of randomization, including a mean IV glucose requirement of ⁇ 10 mg/kg/min to maintain glycemia above 70 mg/dL (3.9 mmol/L) during the 24 hours prior to randomization. Patients were also not randomized if there was use of glucagon or additional enteral glucose within 24 hours prior to randomization.
  • the Glucose Infusion Rate was reviewed hourly, based on an hourly Plasma Glucose (PG) check performed by the StatStrip Xpress2 meter.
  • the IV GIR were reviewed, evaluated, and adjusted (if indicated) according to the IV GIR algorithm based on PG levels specified in the Table 5. If IV glucose were stopped, PG will be checked according to local practice, but at least 3 times daily. Blood for PG check were obtained either by finger or heel sticks or by an indwelling peripheral line.
  • SMPG Self-Measured Plasma Glucose
  • GIR glucose infusion rate
  • IV intravenous Continuous Glucose Monitoring (CGM)
  • Dexcom G4 and Dexcom G6 were used in the clinical trials described in the examples below.
  • Dexcom CGMs (Dexcom G4 and Dexcom G6), configured and labeled for use in the trial, was provided.
  • the Dexcom G4 was be taken off the market by the supplier during 2020 and patients enrolled thereafter were using the Dexcom G6 CGM. Patients using the Dexcom G4 CGM continued using this device throughout the trial and were not switch to the Dexcom G6 device.
  • the CGM were started at least 24 hours prior to randomization and were used during Parts 1 and 2 in a blinded mode to evaluate efficacy in terms of hypoglycemic episodes. Short pauses of 1 to 3 days due to skin irritation or discomfort were allowed during Part 2 of the trial after consultation with the investigator.
  • the CGM devices were calibrated and used according to the manufacturer's instructions; the Dexcom G4 were calibrated 2 times per day, the Dexcom G6 did not require calibration.
  • CGM data were downloaded from the patient's device.
  • the procedure for download of CGM data were described in the pharmacy manual/TMM (trial materials manual).
  • the contract research organization (CRO) or delegate handled the device sourcing, configuration for use in this trial, procedures for blinded data extraction, device service, and handling of potential returns.
  • the parent(s)/guardian received a paper diary to be completed at home.
  • the investigator instructed the patient's parent(s)/guardian on how to complete the diary.
  • the following information were recorded in the diary:
  • Plasma glucose during the last 2 hours was constantly above 120 mg/dL (6.7 mmol/L), or
  • IV GIR had not decreased despite 2 sequential dose increments of IMP (in this situation, the dose of IMP was to be maintained until the IV GIR could be further decreased or until crossover or the end of Part 1), or
  • the 2-hour dose-adjustment interval allowed IMP levels to approach a steady state before the dose was further increased.
  • the cumulative dose did not exceed 1.26 mg over the first 24 hours and 1.68 mg for the subsequent 24-hour periods.
  • the IMP was again to be titrated from the starting dose of 10 pg/hour, and IV GIR was to be set to the rate obtained at the end of the Run-in Period and titrated accordingly. All feedings (administered as parenteral nutrition, by nasogastric [NG] tube, gastrostomy, or normal route), were recorded during this period. Safety assessments were performed throughout the trial. Part 2
  • the baseline weighted mean (SD) IV GIR in the FAS population at the end of the Run-in Period was 15.71 mg/kg/min (4.538).
  • the weighted mean (SD) IV GIR was 4.33 mg/kg/min (4.922) which represents a mean (SD) CFB of -11.38 mg/kg/min (2.770).
  • the weighted mean (SD) IV GIR was 9.51 mg/kg/min
  • FAS Ful I Analysis Set
  • GIR glucose infusion rate
  • IV intravenous
  • the key secondary efficacy endpoint was the total amount (g) of carbohydrates administered (regardless of the route) per day during Part 1 of the trial (Day 1 to 4, for each 48-hour treatment period).
  • the mean (SD) total amount of carbohydrates administered during Part 1 after dasiglucagon treatment was 106.7 g/day (53.72) with median of 99.3 g/day.
  • the mean (SD) total amount of carbohydrates administered was 139.1 g/day (57.35) with median of 134.2 g/day.
  • FAS Full Analysis Set
  • n number of observations
  • N number of patients
  • SD standard deviation
  • Time to complete weaning off IV GIR (time from first exposure during Part 2 to stop of IV glucose infusion) in the FAS population is displayed in Table .
  • Complete weaning off IV GIR was defined as the first point in time when the patient had been off IV GIR for 12 hours. This definition was based on clinical considerations by CHI experts that 12 hours off IV GIR is considered a reasonable indication that patients can manage without IV GIR, even though some of them may need re-initiation of IV glucose at later point. Only patients without complete weaning off IV GIR at the start of Part 2 were included in this analysis.
  • the median (95% Cl) time to complete weaning off IV GIR was 5.8 days (1.0; 7.9) with 2 patients censored at the end of Week 3. At the end of Week 1, 7 patients (58.3%) had weaned off IV GIR; at the end of Week 2 and Week 3, 10 patients (83.33%) had weaned off IV GIR for at least 12 hours.
  • Time to complete weaning off IV glucose defined as the first point in time when the patient had been off IV GIR for 12 hours. It was censored at time of pancreatectomy. Start time was first day of Part 2. Percentages calculated by KM estimates.
  • Prior and concomitant medications were noted by the parent(s)/guardian in the diary. At least 1 prior medication was reported for 11 patients (91.7%). Prior medications by ATC level 4 (or higher) were most frequently reported as:
  • Concomitant medications which were started or changed during the trial were administered to 3 patients (25.0%) when receiving dasiglucagon during Part 1, 4 patients (33.3%) when receiving placebo during Part 1, and to 12 patients (100.0%) during Part 2.
  • the majority of the AEs were mild (63 events out of a total of 76 for both parts and both treatment groups) and considered unrelated to the IMP (65 events out of a total of 76 for both parts and both treatment groups).
  • Gastrointestinal disorders 1 patient (8.33%) in Part 1 during dasiglucagon, 1 patient (8.33%) in Part 1 during placebo, 6 patients (50.00%) in Part 2. These were mainly vomiting, constipation and gastrooesophageal reflux disease.
  • Skin and subcutaneous tissue disorders 1 patient (8.33%) in Part 1 during placebo, 7 patients (58.33%) in Part 2. These were mainly rash papular and dermatitis diaper.
  • Metabolism and nutrition disorders 1 patient (8.33%) in Part 1 during placebo, 5 patients (41.67%) in Part 2. These were mainly hypokalaemia and hyponatraemia.
  • SAEs serious adverse events
  • AESIs adverse events of special interest
  • the trial protocol, consent form and other information provided to participants and parents/legal representatives were approved by independent ethics committees or institutional review boards at participating sites, and by competent authorities.
  • the trial was conducted according to the Declaration of Helsinki and Good Clinical Practice with written informed consent obtained from pa re nts/ca regivers and assent from participants (as required) before trial enrolment.
  • the trial is registered with www.clinicaltrials.gov (NCT03777176).
  • Eligible participants were aged between 3 months and 12 years (both inclusive), had a body weight >4 kg, a documented diagnosis of CHI, and were experiencing >3 episodes of hypoglycaemia/week (self-measured plasma glucose [SMPG] ⁇ 3.9 mmol/L) according to the investigator's evaluation. Patients could either have undergone near-total pancreatectomy (>95%) or be treated non-surgically. Patients requiring exogenous insulin, or who had documented HbAi c >7% (53 mmol/mol) after near-total pancreatectomy (and within 6 months prior to screening) were excluded. Patients were also excluded if there were significant changes to SoC medications during screening or they had received glucagon in the 24 hours prior to randomization. Doses of all SoC medications were to remain stable throughout the trial. If the participant was receiving octreotide or lanreotide, these must have been used for at least 8 and 16 weeks prior to screening, respectively.
  • Table 9 Baseline and demographic characteristics Values are mean (SD) unless otherwise specified; n: number of patients; SoC: standard of care; weight Z-scores (based on the World Health Organization growth charts) were derived using a subject's age and sex.
  • SPG Self-Measured Plasma Glucose
  • CGM Continuous Glucose Monitoring
  • CGM were used (Dexcom G4) in a blinded manner to evaluate efficacy in terms of hypoglycemic episodes.
  • the CGM were supplied for use throughout the trial, and continuous glucose monitoring was required for the 2 weeks up to randomization, during Week 2-4 of Treatment Period 1, and during Week 6-8 of Treatment Period 2. Short pauses of 1-3 days due to skin irritation or discomfort were allowed after consultation with the investigator.
  • CGM data were downloaded from the patient's devices.
  • Dexcom G4 CGMs configured and labeled for use in this trial were provided. Each CGM device were calibrated and used according to the manufacturer's instructions.
  • the contract research organization (CRO) or delegate handled device sourcing, configuration for use in the trial, procedures for blinded data extraction, device service, and return handling.
  • the patient's parent(s)/guardian was provided with a paper diary at all visits except at Visit 7 and the Follow-up Visit.
  • the investigator instructed the patient's parent(s)/guardian on how to complete the diary.
  • the diary was completed throughout the trial until the end of treatment visit (Visit 7). The following information was recorded in the diary:
  • Infusion was initiated at 10 pg/h, with the dose increased by 10 pg/h every 2 hours to a maximum rate of 70 pg/h unless the patient was weaned off gastric dextrose infusion and/or glucose fortified feeds, PG levels during the previous 2 hours were consistently >6.7 mmol/L, or adverse events considered related to dasiglucagon (e.g., nausea and vomiting) limited further dose escalation.
  • the dose increase in dasiglucagon was restricted to achieve the treatment objectives of obtaining a SMPG value between 3.9-6.7 mmol/L while approaching a normal feeding regimen according to age.
  • the dose of dasiglucagon was not escalated beyond reaching the treatment objectives of PG in the range of 70-120 mg/dL (3.9-6.7 mmol/L) while approaching a normal feeding regimen according to age.
  • the 2-hour dose-adjustment interval allowed plasma drug levels to approach approximately steady state before the dose was further increased.
  • the maximum cumulative dose over the first 24 hours was 1.26 mg.
  • CGM continuous glucose monitoring
  • FAS full analysis set
  • n number of observations
  • N number of patients
  • NA not applicable
  • SD standard deviation
  • hypoglycemia was defined as CGM ⁇ 70 mg/dL.
  • Rate of CGM-detected hypoglycemic episodes defined as CGM ⁇ 70 mg/dL for 15 minutes or more per week, was descriptively analyzed for the full analysis set (FAS) population is summarized below.
  • the mean (SD) baseline values were 36.17 (13.263) in the dasiglucagon + standard of care group and 43.16 (23.314) in the standard of care only group.
  • a posthoc analysis of the percent time in CGM-detected clinically significant hypoglycaemia defined as ⁇ 54 mg/dL was expressed for the full analysis set (FAS) population.
  • the baseline was calculated as average percent time ⁇ 54 mg/dL during 14 days before randomization.
  • the mean (SD) baseline time ⁇ 54 mg/dL was 5.90% (4.022) in the dasiglucagon + standard of care group and 7.42% (5.076) in the standard of care only group.
  • CGM continuous glucose monitoring
  • FAS full analysis set
  • n number of observations
  • N number of patients
  • NA not applicable
  • SD standard deviation
  • Rate of clinically significant CGM-detected hypoglycemic episodes defined as CGM ⁇ 54 mg/dL for 15 minutes or more per week, was descriptively analyzed for the FAS population in Treatment Period 1 as a posthoc analysis, and in Treatment Period 2 when all patients received dasiglucagon + standard of care, as a preplanned analysis.
  • the mean (SD) baseline values were 13.87 (8.800) in the dasiglucagon + standard of care group and 18.22 (11.125) in the standard of care only group. During Treatment Period 1, the rate over Weeks 2-4 decreased in both groups.
  • the mean (SD) change from baseline was -5.11 (12.565), i.e., by 36.84%, to the mean (SD) rate of 8.48 (6.556); in the standard of care only group, the mean (SD) change from baseline was - 3.72 (10.787) to the mean (SD) rate of 14.50 (6.248).
  • CGM continuous glucose monitoring
  • FAS full analysis set
  • n number of observations
  • N number of patients
  • NA not applicable
  • PG plasma glucose
  • SD standard deviation
  • Rate of clinically significant hypoglycemic episodes were defined as number of CGM-detected episodes per week.
  • a single CGM-detected clinically significant hypoglycemia episode was defined as CGM ⁇ 54 mg/dL for 15 minutes and up until 60 minutes from the start of the episode even if normoglycemia (>70 mg/dL) was not reached within this time.
  • a new episode of hypoglycemia was reported when the next CGM value below 54 mg/dL was measured for at least 15 minutes.
  • CGM demonstrates dasiglucagon-associated reduction in the risk of nocturnal hypoglycaemia, see Table 14 below.
  • TEAEs treatment emergent adverse events
  • 50 TEAEs were reported for 87.50% of patients in the dasiglucagon + standard of care group versus 11 events reported for 50% of patients in the standard of care group.
  • Vomiting was reported more frequently in the dasiglucagon treatment group compared with those receiving standard of care treatment, consistent with this gastrointestinal event being well-known side effect of glucagon treatment.
  • More cases of skin and subcutaneous tissue disorders were reported for dasiglucagon relative to standard of care treatment. No skin-related events led to permanent discontinuation of dosing.
  • An imbalance of events was noted within the MedDRA system organ class (SOC) of infections and infestations during the initial 4-week trial period; 12 events in the dasiglucagon + standard of care group versus 4 events in the standard of care group.
  • SOC MedDRA system organ class
  • CHI congenital hyperinsulinism
  • Trial 17103 included neonates and infants with CHI aged 7-364 days.
  • Part 1 participants were randomized to receive dasiglucagon or placebo (48 hours each) in a double-blind, crossover design.
  • open-label Part 2 P2
  • Open-label trial 17109 NCT03777176
  • Example 2 included children with CHI aged 3 months to 12 years.
  • Pl participants were randomized to receive standard of care (SoC) or dasiglucagon+SoC for 4 weeks.
  • P2 all participants received dasiglucagon+SoC for 4 weeks.
  • Safety analysis comprised treated participants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne le dasiglucagon, un analogue du glucagon, ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, pour le traitement de l'hyperinsulinisme congénital.
PCT/EP2024/075495 2023-09-15 2024-09-12 Dasiglucagon destiné à être utilisé dans le traitement de l'hyperinsulinisme congénital Pending WO2025056677A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP23197672 2023-09-15
EP23197672.1 2023-09-15
EP23219940 2023-12-22
EP23219940.6 2023-12-22

Publications (1)

Publication Number Publication Date
WO2025056677A1 true WO2025056677A1 (fr) 2025-03-20

Family

ID=92712619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/075495 Pending WO2025056677A1 (fr) 2023-09-15 2024-09-12 Dasiglucagon destiné à être utilisé dans le traitement de l'hyperinsulinisme congénital

Country Status (1)

Country Link
WO (1) WO2025056677A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011125A1 (fr) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Amelioration apportee a une synthese de peptides en phase solide et agent utilise dans ladite synthese
WO2014016300A1 (fr) 2012-07-23 2014-01-30 Zealand Pharma A/S Analogues du glucagon
WO2014124151A1 (fr) 2013-02-06 2014-08-14 Xeris Pharmaceuticals, Inc. Procédés pour traiter rapidement une hypoglycémie sévère
WO2017053822A1 (fr) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Système de suivi d'objet détecté pour un système d'analyse vidéo
WO2021185821A1 (fr) 2020-03-16 2021-09-23 Zealand Pharma A/S Formulations liquides d'analogues du glucagon

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011125A1 (fr) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Amelioration apportee a une synthese de peptides en phase solide et agent utilise dans ladite synthese
WO2014016300A1 (fr) 2012-07-23 2014-01-30 Zealand Pharma A/S Analogues du glucagon
WO2014124151A1 (fr) 2013-02-06 2014-08-14 Xeris Pharmaceuticals, Inc. Procédés pour traiter rapidement une hypoglycémie sévère
WO2017053822A1 (fr) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Système de suivi d'objet détecté pour un système d'analyse vidéo
WO2021185821A1 (fr) 2020-03-16 2021-09-23 Zealand Pharma A/S Formulations liquides d'analogues du glucagon

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Oxford Dictionary Of Biochemistry And Molecular Biology", 2000, OXFORD UNIVERSITY PRESS
"Remington: The Science and Practice of Pharmacy", 1995
"Remington's Pharmaceutical Sciences,", 1985, MACK PUBLISHING COMPANY
"The Dictionary of Cell and Molecular Biology", 1999, ACADEMIC PRESS
ARNOUX JBVERKARRE VSAINT-MARTIN C ET AL.: "Congenital hyperinsulinism: current trends in diagnosis and therapy", ORPHANET J RARE DIS, vol. 6, 2011, pages 63, XP021111093, DOI: 10.1186/1750-1172-6-63
ARYA VBSENNIAPPAN SDEMIRBILEK H ET AL.: "Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism", PLOS ONE, vol. 9, no. 5, 2014, pages e98054
BANERJEE IRASKIN JARNOUX JB ET AL.: "Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families", ORPHANET J RARE DIS, vol. 17, no. 1, 2022, pages 61
CEDERBLAD FEWALD UGUSTAFSSON J: "Effect of glucagon on glucose production, lipolysis, and gluconeogenesis in familial hyperinsulinism", HORM RES, vol. 50, no. 2, 1998, pages 94 - 8
DE COSIO APTHORNTON P: "Current and Emerging Agents for the Treatment of Hypoglycemia in Patients with Congenital Hyperinsulinism", PAEDIATR DRUGS, vol. 21, no. 3, 2019, pages 123 - 36
DE LEON DIVA ET AL: "Dasiglucagon Treatment Over 21 days in Infants with Congenital Hyperinsulinism Results in Glycaemic Stability and Reduces Requirement for Intravenous Glucose", vol. 95, no. Suppl. 2, 1 January 2022 (2022-01-01), CH, pages 61 - 62, XP093126120, ISSN: 1663-2818, Retrieved from the Internet <URL:https://www.karger.com/Article/Pdf/525606> DOI: 10.1159/000525606 *
E.W. MARTIN: "Remington's Pharmaceutical Sciences", 2005
FIELDS, G.B. ET AL.: "Concise Dictionary of Biomedicine and Molecular Biology", 2002, CRC PRESS, article "Principles and practice of solid-phase peptide synthesis"
HOVELMANN UBYSTED BVMOURITZEN U ET AL.: "Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog", DIABETES CARE, vol. 41, no. 3, 2018, pages 531 - 7, XP055739398, DOI: 10.2337/dc17-1402
JONES, A, ADV. DRUG DELIVERY REV, vol. 10, 1993, pages 29 - 90
LORD KRADCLIFFE JGALLAGHER PRADZICK NSSTANLEY CADE LEON DD: "High risk of diabetes and neurobehavioral deficits in individuals with surgically treated hyperinsulinism", J CLIN ENDOCRINOL METAB, vol. 100, no. 11, 2015, pages 4133 - 9
MEISSNER TWENDEL UBURGARD PSCHAETZLE SMAYATEPEK E: "Long-term follow-up of 114 patients with congenital hyperinsulinism", EUR J ENDOCRINOL, vol. 149, no. 1, 2003, pages 43 - 51
ROWE C. RPAUL J. SMARIAN E. Q: "Handbook of Pharmaceutical Excipients", 1991, MARCEL DEKKER, INC, pages: 247 - 301
SALOMON-ESTEBANEZ MYAU DDUNNE MJ ET AL.: "Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series", FRONT ENDOCRINOL (LAUSANNE, vol. 11, 2020, pages 441
THORNTON PAUL ET AL: "4910 Dasiglucagon Treatment Significantly Reduces Rates of Hypoglycemia as Measured by Continuous Glucose Monitoring in Infants and Children with Congenital Hyperinsulinism", vol. 95, no. Suppl. 1, 1 January 2022 (2022-01-01), CH, XP093126118, ISSN: 1663-2818, Retrieved from the Internet <URL:https://karger.com/hrp/article-pdf/95/Suppl.%201/1/4008149/000525242.pdf> DOI: 10.1159/000525242 *
YAU DLAVER TWDASTAMANI A ET AL.: "sing referral rates for genetic testing to determine the incidence of a rare disease: The minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389", PLOS ONE, vol. 15, no. 2, 2020, pages e0228417
ZELAND PHARMA: "Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)", 19 May 2022 (2022-05-19), XP093125700, Retrieved from the Internet <URL:https://www.globenewswire.com/news-release/2022/05/19/2446817/0/en/Zealand-Pharma-Announces-Positive-Results-from-Phase-3-Trial-of-Dasiglucagon-in-Pediatric-Patients-with-Congenital-Hyperinsulinism-CHI.html#:~:text=Dasiglucagon%20met%20the%20primary%20endpoint,months)%20when%20compared%20to%20placeb> [retrieved on 20240131] *

Similar Documents

Publication Publication Date Title
EP3323423B1 (fr) Établissement rapide et/ou arrêt rapide d&#39;une administration constante substantielle de médicament
EP2611458B1 (fr) Utilisation de lixisenatide pour fabrication de médicament pour traitement du diabète sucré de type 2
TWI619724B (zh) 新穎之調酸素衍生物及含有該衍生物之用於治療肥胖之醫藥組成物
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
AU2012257850B2 (en) Lixisenatide as add-on therapy to basal insulin in type 2 diabetes
EP3295952B1 (fr) Formulation pharmaceutique comprenant un analogue du glp-1 et son procédé de préparation
KR102231074B1 (ko) 인슐린 글라진／릭시세나티드 고정비 제형
EP3967755B1 (fr) Npp1 soluble pour une utilisation dans une méthode de traitement du pseudoxanthome élastique
JP2015501314A (ja) ２型糖尿病の治療プロトコル
CN107496907A (zh) 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品
CN105188736A (zh) 胰岛素给药方案
CN102363633A (zh) 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
EP1515749A1 (fr) Utilisation combinee d&#39;un modulateur de cd3 et d&#39;un compose a base de glp-1
TWI811280B (zh) 用fgf21變體治療代謝障礙之方法
US20230414698A1 (en) Collagen 7 compositions and methods of using the same
AU2024219736A1 (en) Sublingual epinephrine tablets
TW202417035A (zh) 提派肽(tirzepatide)組合物及用途
KR20200076705A (ko) 둘라글루티드를 함유하는 조성물 및 사용 방법
WO2025056677A1 (fr) Dasiglucagon destiné à être utilisé dans le traitement de l&#39;hyperinsulinisme congénital
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
KR20260006552A (ko) Igf-1 키메라 단백질을 이용한 치료 방법
US20150132344A1 (en) Oral Leptin Formulations and Uses Thereof
TW202029979A (zh) Glp-2融合多肽及用於治療及預防胃腸病症之用途
HK1185807A (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK1185807B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24768595

Country of ref document: EP

Kind code of ref document: A1